Skip to main content
Clinical Trials/NCT04026932
NCT04026932
Unknown
Not Applicable

The Clinical Effects of Modified Tinnitus Relieving Sound Treatment

Eye & ENT Hospital of Fudan University1 site in 1 country68 target enrollmentAugust 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Tinnitus, Subjective
Sponsor
Eye & ENT Hospital of Fudan University
Enrollment
68
Locations
1
Primary Endpoint
Tinnitus Handicapped Inventory (THI)
Last Updated
6 years ago

Overview

Brief Summary

Objective Tinnitus is one of the most common acoustic disorders by affecting 5-43% people around the world, and tinnitus is harmful to social and individuals, inducing to annoyance, irritability, anxiety, depression, insomnia and concentration difficulties. Many efforts have been made to help tinnitus suffers, however, the curative means are still in absence. This study aims to introduce a novel sound therapy for tinnitus and to evaluate the efficacy of modified tinnitus relieving sound treatment in comparison with unmodified music which served as a control.

Methods and analysis A randomized, triple-blinded, controlled, clinical trial will be carried out. 68 patients with subjective tinnitus will be recruited and randomized into two groups in 1:1 ratio. The primary outcomes will be Tinnitus Handicapped Inventory (THI), Hospital Anxiety and Distress Scale (HADS), and visual analogue scale (VAS) for tinnitus; the secondary outcome measures will be Athens Insomnia Scale (AIS), tinnitus loudness matched by sensation level (LM, SL), and minimum masking level (MML). Assessment will be performed at baseline and at 1, 3, 9, and 12 months post-randomization. The sound stimulus will be persistent until 9 months after randomization, and be interdictory in the last three months.

Registry
clinicaltrials.gov
Start Date
August 2019
End Date
February 2022
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults aged between 18 to 80 years old;
  • Diagnosed with subjective tinnitus;
  • Chronic tinnitus: tinnitus course ≥3 months;
  • Be able to understand and communicate with Mandarin;
  • The average pure tone threshold (0.5, 1, 2kHz) ≤ 55dB HL of the worse ear;
  • Subjects are able to understand the purpose of the study, volunteer to participate and cooperate with the instructors to complete the experiment, and be willing to sign the informed consent.

Exclusion Criteria

  • Pulsatile tinnitus and objective tinnitus;
  • Having significant health issues that affect or prevent participation or continue with the follow-up;
  • Diseases requiring other medical intervention first (eg, infections, tumors, otosclerosis, Meniere's disease, the acute stage of sudden sensorineural hearing loss);
  • People with severe hyperacusis, severe anxiety, depression and other psychiatric disorders;
  • Currently participating in other research projects that may affect tinnitus;
  • Subjects who are not considered suitable for this clinical trial by the researchers.

Outcomes

Primary Outcomes

Tinnitus Handicapped Inventory (THI)

Time Frame: 12 months from baseline

THI is a self-assessment inventory including 25 items with grades four categories of tinnitus severity: slight corresponding to a score 0-16, mild (18-36), moderate (38-56), severe (58-100). The higher the score the more severe the tinnitus.

Hospital Anxiety and Distress Scale (HADS)

Time Frame: 12 months from baseline

HADS includes two subscales for anxiety and depression, each with respective 7 items, and the grades are valued by scoring: negative (0-7), positive (8-21).

Visual Analogue Scale (VAS) for tinnitus

Time Frame: 12 months from baseline

Visual Analogue Scale (VAS) for tinnitus is a universal psychometric scale evaluating subjective tinnintus. A total score is 10, from 0 to 10. The higher the score, the more severe the symptom.

Secondary Outcomes

  • Athens Insomnia Scale (AIS)(12 months from baseline)
  • tinnitus loudness matched by sensation level (LM, SL)(12 months from baseline)
  • minimum masking level (MML)(12 months from baseline)

Study Sites (1)

Loading locations...

Similar Trials